< 生产厂家价格 >

水飞蓟宾A,B(混合物)

水飞蓟宾A,B(混合物)用途

Silybin 是一种从草蓟 (Silybum marianum) 种子中分离出来的黄素寡糖。Silybin 诱导凋亡 (apoptosis),并具有保肝,抗氧化,抗炎,抗癌活性。

点击显示

水飞蓟宾A,B(混合物)名称

[ CAS 号 ]:
802918-57-6

[ 中文名 ]:
水飞蓟宾

[ 英文名 ]:
Silybin

[英文别名 ]:

silibin
silybin
Silybin
Silybin A,B (mixture)

水飞蓟宾A,B(混合物)生物活性

[ 描述 ]:

Silybin 是一种从草蓟 (Silybum marianum) 种子中分离出来的黄素寡糖。Silybin 诱导凋亡 (apoptosis),并具有保肝,抗氧化,抗炎,抗癌活性。

[ 相关类别 ]:

信号通路 >> 细胞凋亡 >> 细胞凋亡

研究领域 >> 癌症

研究领域 >> 炎症/免疫

[体外研究]

水飞蓟宾(0-200mm；72小时)具有时间和剂量依赖性的生长抑制作用[1]。水飞蓟宾(68μM；72小时)诱导细胞凋亡,使G1期细胞增加约22%[1]。水飞蓟宾(68μM；72小时)诱导AKT活性抑制[1]。细胞活力测定[1]细胞系：HepG2细胞生长浓度：0-200mm孵育时间：72h结果：生长抑制呈时间和剂量依赖性,IC50为68μM。凋亡分析[1]细胞系：HepG2细胞生长浓度：68μM孵育时间：72h结果：诱导凋亡的细胞数较多细胞(60%)相比,未经处理的细胞。细胞周期分析[1]细胞系：HepG2细胞生长浓度：68μM孵育时间：72h结果：G1期细胞增加约22%,S期细胞减少47%。westernblot分析[1]细胞株：HepG2细胞生长浓度：68μM孵育时间：72h结果：诱导AKT活性抑制。

[体内研究]

水飞蓟宾(50100毫克/千克/天；过去4周内灌胃给药)显著降低血清和肝脏脂质积聚[2]。动物模型：非酒精性脂肪性肝病(NAFLD)雄性C57BL/6J小鼠(6-8周龄)[2]剂量：50100 mg/kg给药：灌胃给药；每日一次；最后4周结果：显著降低血清和肝脏脂质积聚。

[参考文献]

[1]. Silvia Zappavigna, et al. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. Int J Mol Sci. 2019 May 3;20(9):2190.

[2]. Runbin Sun, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020 Mar;123:109721.

水飞蓟宾A,B(混合物)物理化学性质

[ 熔点 ]:
152-153°C

[ 分子式 ]:
C₂₅H₂₂O₁₀

[ 分子量 ]:
482.43600

[ 精确质量 ]:
482.12100

[ PSA ]:
155.14000

[ LogP ]:
2.36270

[ 储存条件 ]:
Refrigerator

水飞蓟宾A,B(混合物)安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P261-P305 + P351 + P338

[ 危害码 (欧洲) ]:
Xi

[ 风险声明 (欧洲) ]:
36/37/38

[ 安全声明 (欧洲) ]:
26-37/39

[ 危险品运输编码 ]:
NONH for all modes of transport

[ RTECS号 ]:
DJ2981770

水飞蓟宾A,B(混合物)文献

The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity.

J. Pharm. Pharmacol. 66(9) , 1339-46, (2014)

The aim of this study is to establish the inhibitory effects of 14 commonly used complementary and alternative medicines (CAM) on the metabolism of cytochrome P450 2C9 (CYP2C9) substrates 7-methoxy-4-...

Engineered silybin nanoparticles educe efficient control in experimental diabetes.

PLoS ONE 9(7) , e101818, (2014)

Silybin, is one imminent therapeutic for drug induced hepatotoxicity, human prostate adenocarcinoma and other degenerative organ diseases. Recent evidences suggest that silybin influences gluconeogene...

Isolation and purification of diastereoisomeric flavonolignans from silymarin by binary-column recycling preparative high-performance liquid chromatography.

J. Sep. Sci. 37(17) , 2300-6, (2014)

Silymarin extracted from Silybum marianum (L.) Gaertn consists of a large number of flavonolignans, of which diastereoisomeric flavonolignans including silybin A and silybin B, and isosilybin A and is...

更多文献